Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

The immunotherapy developer, which counts Pfizer, Sanofi, Merck & Co, Eli Lilly, Amgen and Vertex Pharmaceuticals as early investors, has picked up $102m.

Pfizer and Lundbeck scored exits as blood-disease therapy developer Imara raised $75.2m, floating at the foot of its range.

The antibody-based drug developer has now raised $210m altogether, with both SK Holdings and Legend Capital backing its series B-plus round.

Humanised antibody-based drug developer Harbour BioMed has now raised $210m altogether following a series B-plus round featuring Zhejiang University Future Capital.

The healthcare access platform developer closed a series A round led by UnityPoint Health Ventures that included fellow corporate VC unit Well Ventures and ThedaCare.

The genetic therapy developer, which had raised $126m in funding from investors including Eli Lilly and Access Industries, added $32.4m to the offering.

Underwriters have exercised their over-allotment option in full, increasing the University of Pennsylvania-linked genetic medicine developer’s proceeds by $32.4m.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.